L-655708 (FG-8094) is a nootropic drug invented in 1996 by a team working for Merck Sharp and Dohme that was the first compound developed which acts as a subtype-selective inverse agonist at the α5 subtype of the benzodiazepine binding site on the GABAA receptor.
This page contains content from the copyrighted Wikipedia article "L-655708"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
